Clinical Trial Update: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the immune response and safety of GlaxoSmithKline's RSV vaccine in adults aged 18 to 49 at increased risk for RSV disease, compared w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Arexvy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2025-09-25